Vancouver, BC – Cancer patients across Canada will benefit from a multi-million dollar investment by The Terry Fox Foundation that will support new and breakthrough research undertaken by leading scientists and clinicians at health and research centres and institutions in British Columbia, Ontario and Quebec.
Focusing on early detection and disease prevention
For original story, click here.
Executive Director of Vancouver Prostate Center Chosen as 'Local Hero' for Contributions to Fight Disease That Affects One in Six Men in Their Lifetime
VANCOUVER, April 21, 2011 (original story at CNW)
Steve Jones, President and CEO, Prostate Cancer Canada and members of the business community today celebrated Dr. Martin Gleave as a 'local hero' for his extraordinary contributions to fight prostate cancer.
Made a New Year’s resolution to get in shape, or stay in shape? Sign up for the fifth annual Harry’s Spring Run-Off 8K To Fight Prostate Cancer on March 20 in Stanley Park and help raise money for prostate cancer research at the Vancouver Prostate Centre. Register now at Canada Running Series and sign up to start fundraising atwww.harryrosenrunforvgh.ca.
Dr. Zoubeidi of Vancouver Prostate Centre one of four to receive award
Vancouver, BC – Today, the Terry Fox Foundation (TFF) announced funding of $1.8 million in career awards to four promising scientists under its New Investigator (NI) Awards program. Three researchers working in British Columbia and a fourth working in Ontario will receive the funds to further their quest to unravel the complexities of cancer.
Vancouver, British Columbia — Two Vancouver researchers are tackling the deadliest forms of prostate cancer,t he most commonly diagnosed male cancer in Canada, using a brand new field of genomics called computational chemogenomics. This new approach uses computer modeling in virtual 3D to predict how different chemicals or drugs will affect cancer tumours.
The Vancouver Prostate Centre today announced a one-year collaborative project with Novartis Pharmaceutical Corporation. The project will use cutting-edge technology to identify and validate the molecular targets that predict cancer sensitivity or insensitivity to specific inhibitors. Ultimately these insights may enable clinicians to more accurately select patients who are likely to benefit from a particular clinical trial.
The Vancouver Sun is running a series of articles on prostate cancer this week.